<DOC>
	<DOCNO>NCT02102516</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics safety postoperative administration SPRIX pediatric patient ( age 0-11 ) undergo open surgical procedure .</brief_summary>
	<brief_title>SPRIX 0 11 Year-Old Patients Undergoing Open Surgical Procedures</brief_title>
	<detailed_description>Evaluate pharmacokinetics safety postoperative administration SPRIX pediatric patient ( age 0-11 ) undergo open surgical procedure .</detailed_description>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<criteria>Male female patient age 0 11 year . Undergoing open surgical procedure expect result least moderate pain base age appropriate scale . Body mass index ( BMI ) â‰¤ 95th percentile age . Surgical procedure would allow subject likely remain hospital morning postoperative day 3 ( complete PK sample collection ) . With parental assistance , willing able complete study procedure pain scale communicate meaningfully study personnel . In generally good health capable undergoing surgery . Females risk pregnancy use acceptable form birth control negative serum urine pregnancy test ( although anticipate 011 year old subject premenarchal ) . Willing refrain use nonstudy analgesic duration study , day surgery postoperative Day 4 . Assents participation his/her parent guardian willing able sign inform consent approve IRB . Surgical procedure perform exclusively laparoscopy . Known allergy sensitivity ketorolac , ethylene diamine tetraacetic acid ( EDTA ) . Prior nasalseptal injury surgery . History peptic ulcer , gastroesophageal reflux , gastrointestinal bleeding . History advance renal impairment risk renal failure due volume depletion . Clinically significant ( Investigator 's opinion ) laboratory test value outside normal range . Use either ( . ) oxycodone dose 30 mg/day ( b . ) equivalent dose another opioid analgesic total half day precede month . The patient require regular use ( daily use least 25 day per month ) 3 month prior surgery NSAID 's , COX2 inhibitor , tramadol , acetaminophen daily dose 2 g management pain . Contraindication use morphine , general anesthetic , bupivacaine , ropivacaine , lidocaine , local anesthetic , muscle relaxant , hydrocodone , ondansetron , acetaminophen ( e.g. , significant history allergic reaction intolerance related substance ) . Known bleed diathesis disorder current use agent affect coagulation . Deep venous thrombosis prophylaxis surgeon 's choice permit postoperatively . Current use Central Nervous System ( CNS ) active drug benzodiazepine , tricyclic antidepressant , Selective Serotonin Reuptake Inhibitors ( SSRIs ) pain . These drug permit nonpain indication dose stable least 30 day . The use lorazepam sleep medication , except contain analgesic property , permit . Current diabetes mellitus HbA1C &gt; 9.5 history prolong uncontrolled diabetes . Use antihypertensive agent diabetic regimen dose stable least 30 day . Any medical condition investigator 's opinion could adversely impact patient 's participation safety , conduct study , interfere pain assessment , include active infection . History drug , prescription medicine , alcohol abuse would interfere subject 's safety assessment efficacy trial , judgement investigator . History nasal mucosal damage active seasonal allergy , nasal congestion upper respiratory tract infection sufficient interfere intranasal drug delivery . Administration investigational product within 3 month prior first dose study drug , schedule receive investigational product , participate study . Use Toradol ( ketorolac tromethamine ) formulation within past 30 day prior study entry throughout study participation .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Post operative pain management</keyword>
</DOC>